<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1111246173
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AZIMAC 500 mg
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AZITHROMYCIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        32.30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01FA10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>This medicine contains azithromycin, which is one of a group of antibiotics called macrolides. It is used to treat infections caused by certain bacteria and other microorganisms, which include:</p><ul><li>chest, throat or nasal infections (such as bronchitis, pneumonia, tonsillitis, sore throat (pharyngitis) and sinusitis)</li><li>ear infections</li><li>skin and soft tissue infections (such as an abscess or boil)</li><li>sexually transmitted diseases caused by organisms called <em>Chlamydia trachomatis</em> and <em>Neisseria gonorrhoea.</em></li></ul><p>You must talk to a doctor if you do not feel better or if you feel worse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Azimac:</strong></p><ul><li>if you are allergic to azithromycin or any other macrolide antibiotic such as erythromycin or clarithromycin or any of the ingredients of this medicine (listed in section 6). An allergic reaction may cause skin rash or wheezing.</li></ul><p><strong>&nbsp;</strong></p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Azimac if you have or have had any of the following conditions:</p><ul><li>kidney problems</li><li>heart conditions</li><li>liver problems: your doctor may need to monitor your liver function or stop the treatment</li><li>myasthenia gravis (a condition that causes certain muscles to become weak)</li><li>or if you are taking any ergot derivatives such as ergotamine (used to treat migraine) as these medicines should not be taken together with Azimac.</li></ul><p>Tell your doctor immediately if you feel your heart beating in your chest or have an abnormal heartbeat, or get dizzy or faint or suffer from any muscle weakness when taking Azimac.</p><p>If you develop diarrhoea or loose stools during or after treatment, tell your doctor at once. Do not take any medicine to treat your diarrhoea without first checking with your doctor. If your diarrhea continues, please inform your doctor.</p><p><strong>&nbsp;</strong></p><p><strong>You should know that using azithromycin for long-term to prevent bronchiolitis obliterans syndrome (BOS) following Hematopoietic Stem Cell Transplantation (HSCT) may include risks that exceed the anticipated benefits. Safety of prophylactic long-term azithromycin treatment in this patient group is questioned .</strong></p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Azimac</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>In particular, Azimac may interact with the medicines listed below:</p><ul><li>ergot or ergotamine &ndash; see &lsquo;Warnings and precautions&rsquo; section</li><li>warfarin or any similar medicine to prevent blood clots</li><li>ciclosporin (used to suppress the immune system to prevent and treat rejection of a transplanted organ or bone marrow)</li><li>antacids (for indigestion)</li><li>digoxin (used to treat heart failure)</li><li>colchicine (used for gout and familial Mediterranean fever)</li><li>terfenadine (for hay fever or a skin allergy).</li></ul><p>&nbsp;</p><p><strong>Azimac with food and drink</strong></p><p>You should take Azimac either 1 hour before a meal or 2 hours after a meal.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Azimac is not expected to affect your ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. </strong></p><p>The Tablets should be swallowed whole.</p><p>The recommended dose in adults and children over 45kg is 500mg, once a day, for 3 days.</p><p>For some diseases such as Chlamydia the recommended dose is 1g on one day only.</p><p>For gonorrhoea the recommended dose is 1g or 2g of azithromycin in combination with 250 or 500mg of ceftriaxone.</p><p>Azimac Tablets should not be taken by children weighing less than 45kg.</p><p>You should tell your doctor if you have kidney or liver problems as your doctor may need to alter the normal dose.</p><p>Doctors sometimes prescribe different doses to the recommended dose. The label on the pack will tell you which dose you should take.</p><p>If you are still not sure, ask your doctor or pharmacist.</p><p>Always continue with the course even if you feel better. If your infection gets worse or you do not start to feel better within a few days or a new infection develops, go back and see your doctor.</p><p><strong>If you take more Azimac than you should</strong></p><p>If you take too much Azimac you may feel unwell. Tell your doctor or contact your nearest hospital casualty department immediately.</p><p><strong>If you forget to take Azimac</strong></p><p>If you forget to take Azimac take it as soon as you can. Take your next dose at the right time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Azimac</strong></p><p>If you stop taking Azimac too soon, the infection may return. Take the Tablets for the full time of treatment, even when you begin to feel better.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Like all medicines, this medicine can cause side effects, although not everybody gets them. </strong></p><p><strong>Tell your doctor immediately if you experience any of the following symptoms after taking this medicine as the symptoms can be severe.</strong></p><ul><li>sudden wheeziness, difficulty in breathing, swelling of eyelids, face or lips, rash or itching (especially affecting the whole body)</li><li>severe or prolonged diarrhoea, which may have blood or mucus in it, during or after treatment with Azimac as this may be a sign of serious bowel inflammation</li><li>severe skin rash causing redness and flaking</li><li>rapid or irregular heartbeat</li><li>low blood pressure</li><li>Serious skin reactions:</li></ul><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering of the skin, mouth, eyes and genitals (Stevens-Johnson Syndrome ((SJS)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blistering of the skin, severe skin reaction(Toxic Epidermal Necrosis ) (TEN)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash accompanied by other symptoms such as fever, swollen glands and an increase of eosinophils (a type of white blood cell). A rash appears as small, itchy red bumps (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin eruption that is characterised by the rapid appearance of areas of red skin studded with small pustules (small blisters filled with white/yellow fluid) (Acute Generalised Exanthematous Pustulosis ((AGEP).</p><p>Stop taking azithromycin if you develop these skin symptoms and contact your doctor or seek medical attention immediately.</p><p>The most common side effects that occur when taking Azimac are listed below.</p><p>These may go away during treatment as your body adjusts to the medicine. Tell your doctor if any of these side effects continue to bother you.</p><p><strong>Very common: </strong>may affect more than 1 in 10 people</p><ul><li>stomach cramps, feeling sick, diarrhoea, wind</li></ul><p><strong>Common: </strong>may affect up to 1 in 10 people</p><ul><li>dizziness, headache</li><li>numbness or pins and needles</li><li>being sick, indigestion</li><li>loss of appetite, taste disturbance</li><li>visual disturbances, deafness</li><li>skin rash and /or itching</li><li>joint pain</li><li>low numbers of lymphocytes (a type of white blood cell), higher number of eosinophils (a type of white blood cell)</li><li>low blood bicarbonate</li><li>tiredness or weakness</li></ul><p><strong>Uncommon: </strong>may affect up to1 in 100 people</p><ul><li>yeast infections of the mouth and vagina (thrush)</li><li>low numbers of leukocytes (a type of white blood cell), low number of neutrophils (a type of white blood cell)</li><li>allergic reactions of various severity</li><li>skin more sensitive to sunlight than normal</li><li>feeling nervous</li><li>reduced sense of touch or sensation (hypoesthesia)</li><li>sleepiness or sleeplessness (insomnia)</li><li>poor hearing or ringing in the ears</li><li>heart palpitations, chest pain</li><li>constipation, stomach pain associated with diarrhoea and fever</li><li>inflammation of the liver (hepatitis), changes in liver enzymes</li><li>general loss of strength</li><li>swelling</li><li>general discomfort</li><li>abnormal laboratory test values (e.g. blood or liver tests).</li></ul><p><strong>Rare: </strong>may affect up to 1 in 1,000 people</p><ul><li>agitation</li><li>vertigo</li></ul><ul><li>changes in liver function</li></ul><p><strong>Not known: frequency cannot be estimated from the available data</strong></p><ul><li>fits or fainting</li><li>aggression or anxiety</li><li>feeling hyperactive</li><li>localised muscle weakness</li><li>loss of smell or altered sense of smell, loss of taste</li><li>tongue discolouration</li><li>inflammation of the pancreas (pancreatitis)</li><li>inflammation of the kidney or kidney failure</li><li>yellowing of the skin or eyes (jaundice) or liver failure (rarely life-threatening)</li><li>bruising or prolonged bleeding after injury</li><li>abnormal electrocardiogram (ECG)</li><li>reduction in red blood cells which can make the skin pale and cause weakness or breathlessness.</li></ul><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. </strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not refrigerate.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original package in order to protect from light and moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use AZIMAC after the expiry date which is stated on the package.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each Tablet contains Azithromycin dihydrate (USP) equivalent to Azithromycin 250 mg or 500 mg .</p><p>Other ingredients: Calcium hydrogen phosphate ,croscarmellose sodium , Maize starch , Povidone K-90 ,Sodium Lauryl Sulfate , Magnesium Stearate , Colloidal anhydrous silica ,</p><p>Coating material : Opadry I YS-IR -7003</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                AZIMAC 250 mg: white to off white circular, biconvex, film coated tablets, having MC22 on one side and plain on the other side.
AZIMAC 500 mg: white to off white capsule shaped, biconvex, film coated tablets, having MC23 on one side and break line on the other side.

PRESENTATION:
AZIMAC 250 mg: Opaque PVC-PVDC film / Aluminium foil blister pack of 6 tablets.
AZIMAC 500 mg: Opaque PVC-PVDC film / Aluminium foil blister pack of 3 tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O. Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing authorization holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                4/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي هذا الدواء على أزيثروميسين ، وهو واحد من مجموعة من المضادات الحيوية تسمى الماكروليدات. يتم استخدامه لعلاج الالتهابات التي تسببها بعض البكتيريا والكائنات الحية الدقيقة الأخرى ، والتي تشمل:</p><ul><li>التهابات في الصدر والحنجرة أو الأنف (مثل التهاب الشعب الهوائية والالتهاب الرئوي والتهاب اللوزتين والتهاب الحلق (التهاب البلعوم) والتهاب الجيوب الأنفية)</li><li>&nbsp;التهابات الأذن</li><li>التهابات الجلد والأنسجة الرخوة (مثل خراج أو دمل)</li><li>الأمراض المنقولة جنسيا التي تسببها الكائنات الحية المسماة كلاميديا تراكوماتيس ونيسيريا السيلان.</li></ul><p>يجب أن تتحدث مع طبيب إذا لم تشعر بتحسن أو إذا كنت تشعر بأنك أسوأ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول أزيماك </strong><strong>:</strong></p><ul><li>إذا كان لديك حساسية من أزيثروميسين أو أي مضاد حيوي آخر من الماكروليدات مثل الإريثروميسين أو كلاريثرومايسين أو أي من مكونات هذا الدواء (المذكورة في القسم 6). تفاعل الحساسية قد يسبب طفح جلدي أو صفير عند التنفس.</li></ul><p>&nbsp;</p><p><strong>التحذيرات والاحتياطات </strong></p><p>تحدث إلى طبيبك أو الصيدلي قبل تناول أزيماك &nbsp;إذا كان لديك أي من الحالات التالية:</p><ul><li>مشاكل في الكلى</li><li>أمراض القلب</li><li>مشاكل الكبد: قد يحتاج طبيبك إلى مراقبة وظائف الكبد أو وقف العلاج</li><li>الوهن العضلي الشديد (حالة تسبب ضعف بعض العضلات)</li><li>أو إذا كنت تتناول أي من مشتقات الإرجوت مثل الإرجوتامين (المستخدم لعلاج الصداع النصفي) ، فلا ينبغي تناول هذه الأدوية مع أزيماك.</li></ul><p>&nbsp;</p><p>أخبر طبيبك فوراً إذا شعرت بنبضات قلبك في صدرك أو لديك ضربات قلب غير طبيعية ، أو مصاب بالدوار أو الإغماء أو تعاني من أي ضعف عضلي عند تناول أزيماك.</p><p>إذا أصبت بالإسهال أو براز رخو أثناء العلاج أو بعده ، أخبر طبيبك فورا. لا تتناول أي دواء لعلاج الإسهال دون مراجعة طبيبك. إذا استمر الإسهال ، يرجى إبلاغ طبيبك.<strong>&nbsp;</strong></p><p><strong>يجب أن تعلم أن استخدام أزيثروميسين على المدى الطويل للوقاية من متلازمة التهاب القصبات الهوائية</strong><strong>(BOS) </strong><strong>&nbsp;بعد زرع الخلايا الجذعية المكونة للدم</strong><strong> (HSCT) </strong><strong>قد ينطوي على مخاطر قد تتجاوز الفوائد المتوقعة. سلامة العلاج الوقائي طويل الأمد بالأزيثروميسين في هذه المجموعة من المرضى هو موضع شك .</strong>[m1]&nbsp;<strong>&nbsp;</strong></p><p><strong>أزيماك والأدوية الأخرى </strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول ، أو تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p>على وجه الخصوص ،أزيماك قد يتفاعل مع الأدوية المدرجة أدناه:</p><ul><li>الإرجوت أو الإرجوتامين - راجع قسم &quot;التحذيرات والاحتياطات&quot;</li><li>الوارفارين أو أي دواء مشابه لمنع تجلط الدم</li><li>السيكلوسبورين (يستخدم لتثبيط جهاز المناعة لمنع وعلاج رفض العضو المزروع أو نخاع العظم)</li><li>مضادات الحموضة (لعسر الهضم)</li><li>الديجوكسين (يستخدم لعلاج قصور القلب)</li><li>الكولشيسين (يستخدم لعلاج النقرس وحمى البحر الأبيض المتوسط)</li><li>تيرفينادين (لحمى القش أو حساسية الجلد).</li></ul><p>&nbsp;</p><p><strong>أزيماك</strong><strong> </strong><strong>مع الطعام والشراب</strong></p><p>يجب أن تتناول أزيماك قبل ساعة من الوجبة أو بعد ساعتين من الوجبة.</p><p>&nbsp;</p><p><strong>الحمل والرضاعة الطبيعية والخصوبة</strong></p><p>إذا كنتي حاملاً أو تستخدمين الرضاعة الطبيعية ، تفكرين أنكي قد تكونين حاملاً أو تخططين لإنجاب طفل ، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء.</p><p>&nbsp;</p><p><strong>القيادة واستخدام الآلات</strong></p><p>من غير المتوقع أن يؤثر أزيماك على قدرتك على قيادة أو استخدام الآلات.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>تناول دائما هذا الدواء تماما كما قد أخبرك طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</strong></p><p>يجب ابتلاع الأقراص بالكامل.</p><p>الجرعة الموصى بها عند البالغين والأطفال فوق 45 كجم هي 500 ملجم ، مرة واحدة في اليوم ، لمدة 3 أيام.</p><p>لبعض الأمراض مثل الكلاميديا, الجرعة الموصي بها هي 1 جرام في اليوم.</p><p>لمرض السيلان ، الجرعة الموصى بها هي 1 جرام أو 2 جرام من أزيثروميسين بالاشتراك مع 250 أو 500 ملجم من سيفترياكسون.</p><p>لا ينبغي إعطاء أقراص أزيماك للأطفال الذين يزنون أقل من 45كجم .</p><p>يجب أن تخبر طبيبك إذا كان لديك مشاكل في الكلى أو الكبد حيث قد يحتاج طبيبك إلى تغيير الجرعة المعتادة.</p><p>يصف الأطباء أحيانًا جرعات مختلفة عن الجرعة الموصي بها. سيخبرك الملصق الموجود على العبوة بالجرعة التي يجب أن تتناولها.</p><p>إذا كنت لا تزال غير متأكد ، اسأل طبيبك أو الصيدلي.</p><p>استمر دائمًا في العلاج حتى إذا كنت تشعر بتحسن. إذا ازدادت الإصابة بالعدوى سوءًا أو لم تشعر بالتحسّن في غضون بضعة أيام أو إذا ظهرت عدوى جديدة ، راجع طبيبك.</p><p><strong>إذا تناولت أقراص أزيماك أكثر مما يجب</strong></p><p>إذا تناولت الكثير من أزيماك قد تشعر بتوعك. أخبر طبيبك أو اتصل بأقرب قسم للإصابات في المستشفى على الفور.<strong>&nbsp;</strong></p><p><strong>إذا نسيت تناول أقراص</strong><strong> </strong><strong>أزيماك</strong></p><p>إذا نسيت أن تتناول أزيماك , تناول الأقراص بأسرع ما يمكن. خذ الجرعة التالية في الوقت المناسب. لا تأخذ جرعة مضاعفة للتعويض عن جرعة منسية.</p><p><strong>إذا توقفت عن تناول أقراص</strong><strong> </strong><strong>أزيماك</strong></p><p>إذا توقفت عن تناول أزيماك مبكرا ، قد تعود العدوى. تناول الأقراص لكامل مدة العلاج ، حتى عندما تشعر بتحسن.</p><p><strong>إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، على الرغم من أن ليس كل شخص يحدث له</strong></p><p><strong>أخبر طبيبك فوراً إذا واجهت أي من الأعراض التالية بعد تناول هذا الدواء لأن الأعراض قد تكون شديدة</strong><strong>.</strong></p><ul><li>أزيز مفاجئ أو صعوبة في التنفس أو تورم في الجفون أو الوجه أو الشفتين أو طفح جلدي أو حكة (خاصة اذا كان التأثير على الجسم كله)</li><li>الإسهال الحاد أو المطوَّل ، الذي قد يحتوي على دم أو مخاط ، أثناء أو بعد العلاج بأزيماك لأن هذا قد يكون علامة على التهاب شديد في الأمعاء.</li><li>طفح جلدي شديد يسبب الاحمرار و تقشير</li><li>سرعة ضربات القلب أو عدم انتظامها</li><li>ضغط دم منخفض</li></ul><p>ردود فعل جلدية خطيرة:</p><p>-&nbsp; تقرحات في الجلد والفم والعينين والأعضاء التناسلية (متلازمة ستيفنز جونسون) &nbsp;(SJS)</p><p>- تقرحات في الجلد ، ردة فعل شديدة للجلد (نخر البشرة السامة) (TEN)</p><p>- طفح جلدي مصحوب بأعراض أخرى مثل الحمى وتورم الغدد وزيادة في عدد الخلايا الحمضية (نوع من خلايا الدم البيضاء). يظهر الطفح الجلدي كمطبات حمراء صغيرة وحكة (التفاعلات الدوائية مع فرط الخلايا الحمضية والأعراض الجهازية) &nbsp;(DRESS)</p><p>- فوران الجلد الذي يتميز باحمرار سريع لمناطق من الجلد مرصعة ببثرات صغيرة (بثور صغيرة مملوءة بسائل أبيض / أصفر) (بثورالطفح الظاهري الحاد المعمم)(AGEP).</p><p>&nbsp;</p><p>توقف عن تناول أزيثروميسين إذا كنت تعاني من هذه الأعراض الجلدية واتصل بطبيبك للحصول على الرعاية الطبية على الفور.</p><p>&nbsp;</p><p>الآثار الجانبية الأكثر شيوعا التي تحدث عند تناول أزيماك مذكورة أدناه.</p><p>قد تختفي هذه الأعراض أثناء العلاج حيث يتكيف جسمك مع الدواء. أخبر طبيبك إذا كان أي من هذه الآثار الجانبية تستمر في إزعاجك.</p><p>&nbsp;</p><p><strong>شائعة جدًا:</strong> قد تؤثر على أكثر من شخص من كل 10 أشخاص</p><ul><li>تشنجات في المعدة والشعور بالمرض والإسهال وريح</li></ul><p>&nbsp;</p><p><strong>شائعة:</strong> قد تؤثر على ما يصل الى شخص واحد من كل 10 أشخاص</p><ul><li>الدوخة والصداع</li><li>شعور بخدر أو دبابيس وإبر</li><li>الشعور بالمرض ،</li><li>عسر الهضمفقدان الشهية ، اضطراب التذوق</li><li>الاضطرابات البصرية ، الصمم</li><li>طفح جلدي و / أو حكة</li><li>ألم المفاصل</li><li>انخفاض عدد الخلايا الليمفاوية (نوع من خلايا الدم البيضاء) ، وعدد أكبر من الخلايا الحمضية (نوع من خلايا الدم البيضاء)</li><li>بيكربونات منخفضة في الدم</li><li>التعب أو الضعف</li></ul><p>&nbsp;</p><p><strong>غير شائعة:</strong> قد تؤثر على ما يصل إلى شخص واحد من كل 100 شخص</p><ul><li>عدوى فطرية في الفم والمهبل (القلاع)</li><li>أعداد منخفضة من الكريات البيض (نوع من خلايا الدم البيضاء) ، عدد منخفض من العدلات (نوع من خلايا الدم البيضاء)</li><li>تفاعلات الحساسية مختلفة الشدة</li><li>البشرة أكثر حساسية لأشعة الشمس أكثر من المعتاد</li><li>الشعور بالعصبية</li><li>انخفاض الشعور باللمس أو الإحساس (ضعف الحس)</li><li>النعاس أو الأرق</li><li>ضعف السمع أو الرنين في الأذنين</li><li>خفقان القلب وألم في الصدر</li><li>الإمساك وآلام المعدة المرتبطة بالإسهال والحمى</li><li>التهاب الكبد ، تغييرات في إنزيمات الكبد</li><li>الفقدان العام للقوة</li><li>تورم</li><li>احساس عام بعدم الراحة</li><li>قيم الاختبارات المختبرية غير طبيعية (مثل اختبارات الدم أو الكبد).</li></ul><p>&nbsp;</p><p><strong>نادرة:</strong> قد تؤثر على شخص من كل 1،000 شخص</p><ul><li>الإثارة</li><li>الدوار</li><li>تغيرات في وظائف الكبد</li></ul><p>&nbsp;</p><p><strong>غير معروفة</strong>: لا يمكن تقدير التكرار من البيانات المتاحة</p><ul><li>نوبات أو إغماء</li><li>العدائية أو القلق</li><li>الشعور بفرط النشاط</li><li>ضعف موضعي للعضلات</li><li>فقدان الرائحة أو تغيير حاسة الشم وفقدان حاسة التذوق</li><li>تغير لون اللسان</li><li>التهاب البنكرياس</li><li>التهاب في الكلى أو فشل كلوي</li><li>اصفرار الجلد أو العين (اليرقان) أو فشل الكبد (نادرًا ما يهدد الحياة)</li><li>كدمات أو نزيف مستمر بعد الإصابة</li><li>تخطيط كهربية القلب غير طبيعي (ECG)</li><li>انخفاض في خلايا الدم الحمراء التي يمكن أن تجعل البشرة شاحبة وتسبب ضعف أو ضيق في التنفس.<strong>&nbsp;</strong></li></ul><p><strong>إذا أصبح أي من الآثار الجانبية خطيراً، أو إذا لاحظت أي آثار جانبية غير المذكورة في النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ بعيداً عن متناول ومرأى الأطفال.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة اقل من 30 درجة مئوية.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تحفظ في الثلاجة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في العبوة الأصلية من أجل حمايته من الضوء أو الرطوبة</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم أزيماك بعد تاريخ انتهاء الصلاحية المطبوع على العبوة.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا ينبغي التخلص من الأدوية في مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي حول كيفية التخلص من الأدوية التي لم تعد مطلوبة. ومن شأن هذه التدابير أن تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل قرص يحتوي على أزيثروميسين داي هيدرات (دستور الأدوية الأمريكي) ما يعادل أزيثروميسين 250 ملجم أو 500 ملجم.</p><p>المكونات الأخرى: فوسفات هيدروجين الكالسيوم ، صوديوم كارميللوز ، نشا الذرة ، بوفيدون K-90 ، كبريتات لوريل الصوديوم ، مغنيسيوم ستياريت ، السيليكا الغروية اللا مائية</p><p>مواد الغلاف: أوبادري I YS-IR -7003.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أزيماك 250 ملجم : أقراص دائرية بيضاء إلى أبيض داكن ، محدبة الشكل و مغلفة ،مع وجود MC22 على جانب واحد و مسطحة على الجانب الآخر. أزيماك 500 ملجم : أقراص على شكل كبسولة بيضاء إلى أبيض داكن ، محدبة الشكل و مغلفة ،مع وجود MC23 على جانب واحد ، وخط فاصل على الجانب الآخر. الشكل الصيدلاني : ازيماك 250 ملجم : شريط معتم من الالومنيوم /PVC-PVDC يحتوي على 6 اقراص ازيماك 500 ملجم : شريط معتم من الالومنيوم /PVC-PVDC يحتوي على 3 اقراص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة المنتجات الطبية والتجميلية المحدودة ( الرياض فارما)</p><p>ص.ب. 442 الرياض 11411</p><p>فاكس: 966112650505+</p><p>البريد الإلكتروني: contact@riyadhpharma.com</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على&nbsp; صاحب الترخيص والتسويق:</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111+</p><p>البريد الإلكتروني: marketing@riyadhpharma.com</p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azimac 250 mg film-coated tablets 
Azimac 500 mg film-coated tablets 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azimac 250mg : Each Tablet contains azithromycin dihydrate 262.05 mg equivalent to 250 mg azithromycin base.
Azimac 500mg : Each Tablet contains azithromycin dihydrate 524.00 mg equivalent to 250 mg azithromycin base.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

AZIMAC 250 mg: white to off white circular, biconvex, film coated tablets, having MC22 on one side and plain on the other side.
AZIMAC 500 mg: white to off white capsule shaped, biconvex, film coated tablets, having MC23 on one side and break line on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azithromycin is indicated for the treatment of the following infections when known or likely to be due to one or more susceptible microorganisms (see section 5.1):</p><p>- bronchitis</p><p>- community-acquired pneumonia</p><p>- sinusitis</p><p>- pharyngitis/tonsillitis (see section 4.4 regarding streptococcal infections)</p><p>- otitis media</p><p>- skin and soft tissue infections</p><p>- uncomplicated genital infections due to&nbsp;<em>Chlamydia trachomatis and Neisseria gonorrhoeae.</em></p><p>Considerations should be given to official guidance regarding the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology:</u></p><p>Azimac Tablets should be given as a single daily dose.</p><p>In common with many other antibiotics Azimac Tablets should be taken at least 1 hour before or 2 hours after food.</p><p><strong>Children over 45 kg body weight and</strong>&nbsp;<strong>adults, including elderly patients</strong>:</p><p>The total dose of azithromycin is 1500 mg which should be given over three days (500 mg once daily).</p><p>In uncomplicated genital infections due to&nbsp;<em>Chlamydia trachomatis</em>, the dose is 1000 mg as a single oral dose. For susceptible&nbsp;<em>Neisseria gonorrhoeae</em>&nbsp;the recommended dose is 1000 mg or 2000 mg of azithromycin in combination with 250 mg or 500 mg ceftriaxone according to local clinical treatment guidelines. For patients who are allergic to penicillin and/or cephalosporins, prescribers should consult local treatment guidelines.</p><p><strong>Paediatric population:</strong></p><p><strong>In children under 45 kg body weight</strong>: Azimac Tablets are not suitable for children under 45 kg.</p><p><strong>Renal impairment:</strong></p><p>No dose adjustment is necessary in patients with mild to moderate renal impairment (GFR 10 - 80 ml/min). Caution should be exercised when azithromycin is administered to patients with severe renal impairment (GFR &lt; 10 ml/min) (see section 4.4 and section 5.2).</p><p><strong>Hepatic impairment:</strong></p><p>Since azithromycin is metabolised in the liver and excreted in the bile, the drug should not be given to patients suffering from severe liver disease. No studies have been conducted regarding treatment of such patients with azithromycin (see section 4.4).</p><p><u>Method of administration</u>:</p><p>Azimac Tablets are for oral administration only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Azimac is contra-indicated in patients with a known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic, or to any of the excipients (listed in section 6.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity</u></p><p>As with erythromycin and other macrolides, serious allergic reactions including angioneurotic oedema and anaphylaxis (rarely fatal), Acute Generalized Exanthematous Pustulosis (AGEP) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported. Some of these reactions with azithromycin have resulted in recurrent symptoms and required a longer period of observation and treatment.</p><p><u>Hepatotoxicity</u></p><p>Since the liver is the principal route of elimination for azithromycin, the use of azithromycin should be undertaken with caution in patients with significant hepatic disease. Cases of fulminant hepatitis potentially leading to life-threatening liver failure have been reported with azithromycin (see section 4.8). Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products.</p><p>In case of signs and symptoms of liver dysfunction, such as rapid developing asthenia associated with jaundice, dark urine, bleeding tendency or hepatic encephalopathy, liver function tests/ investigations should be performed immediately. Azithromycin administration should be stopped if liver dysfunction has emerged.</p><p><u>Ergot derivatives</u></p><p>In patients receiving ergot derivatives, ergotism has been precipitated by co-administration of some macrolide antibiotics. There are no data concerning the possibility of an interaction between ergot and azithromycin. However, because of the theoretical possibility of ergotism, azithromycin and ergot derivatives should not be co-administrated.</p><p><u>Prolongation of the QT interval</u></p><p>Prolonged cardiac repolarisation and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen in treatment with other macrolides. A similar effect with azithromycin cannot be completely ruled out in patients at increased risk for prolonged cardiac repolarisation (see section 4.8); therefore caution is required when treating patients:</p><p>&bull; With congenital or documented QT prolongation</p><p>&bull; Currently receiving treatment with other active substance known to prolong QT interval such as antiarrhythmics of Classes Ia and III, cisapride and terfenadine</p><p>&bull; With electrolyte disturbance, particularly in case of hypokalaemia and hypomagnesemia</p><p>&bull; With clinically relevant bradycardia, cardiac arrhythmia or severe cardiac insufficiency.</p><p><u>Superinfection</u></p><p>As with any antibiotic preparation, observation for signs of superinfection with non-susceptible organisms including fungi is recommended.</p><p><em><u>Clostridium difficile</u></em><u>&nbsp;associated diarrhoea</u></p><p><em>Clostridium difficile</em>&nbsp;associated diarrhoea (CDAD) has been reported with the use of nearly all antibacterial agents, including azithromycin, and may range in severity from mild diarrhoea to fatal colitis. Strains of&nbsp;<em>C. difficile</em>&nbsp;producing hypertoxin A and B contribute to the development of CDAD. Hypertoxin producing strains of&nbsp;<em>C. difficile&nbsp;</em>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. Therefore, CDAD must be considered in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Careful medical history is necessary since CDAD has been reported to occur over 2 months after the administration of antibacterial agents. Discontinuation of therapy with azithromycin and the administration of specific treatment for&nbsp;<em>C. difficile</em>&nbsp;should be considered.</p><p><u>Streptococcal infections</u></p><p>Penicillin is usually the first choice for treatment of pharyngitis/tonsillitis due to&nbsp;<em>Streptococcus pyogenes</em>&nbsp;and also for prophylaxis of acute rheumatic fever. Azithromycin is in general effective against streptococcus in the oropharynx, but no data are available that demonstrate the efficacy of azithromycin in preventing acute rheumatic fever.</p><p><u>Renal impairment</u>:</p><p>In patients with severe renal impairment (GFR &lt;10 ml/min) a 33% increase in systemic exposure to azithromycin was observed (see section 5.2).</p><p><u>Myasthenia gravis</u></p><p>Exacerbations of the symptoms of myasthenia gravis and new onset of myasthenia syndrome have been reported in patients receiving azithromycin therapy (see section 4.8).</p><p><u>Diabetes</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>This medicinal product contains sulphur dioxide which may rarely cause severe hypersensitivity reactions and bronchospasm.</p><p>Azimac tablets are for oral administration only.</p><p>&nbsp;</p><p>The long-term azithromycin exposure following HSCT may include risks that exceed the anticipated benefits. Safety of prophylactic long-term azithromycin treatment in this patient group is questioned.</p><p>&nbsp;</p><p>&nbsp;&ldquo;A clinical trial ALLOZITHRO that investigated long-term azithromycin to prevent bronchiolitis obliterans syndrome (BOS) in patients who underwent allogenic Hematopoietic Stem Cell Transplantation (HSCT) for hematological malignancy was terminated early after an increased rate of mortality and relapses of haematological malignancies was seen in patients taking azithromycin compared with placebo&rdquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Antacids</strong>: In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with azithromycin, no effect on overall bioavailability was seen, although peak serum concentrations were reduced by approximately 24%. In patients receiving both azithromycin and antacids, the drugs should not be taken simultaneously.</p><p><strong>Cetirizine:</strong>&nbsp;In healthy volunteers, co-administration of a 5-day regimen of azithromycin with 20 mg cetirizine at steady-state resulted in no pharmacokinetic interaction and no significant changes in the QT interval.</p><p><strong>Didanosine</strong>&nbsp;<em>(Dideoxyinosine)</em>: Co-administration of 1200 mg/day azithromycin with 400 mg/day didanosine in six HIV-positive subjects did not appear to affect the steady-state pharmacokinetics of didanosine as compared to placebo.</p><p><strong>Digoxin and colchicine</strong>: concomitant administration of macrolide antibiotics, including azithromycin, with P-glycoprotein substrates such as digoxin and colchicine, has been reported to result in increased serum levels of the P-glycoprotein substrate. Therefore, if azithromycin and P-glycoprotein substrates such as digoxin are administered concomitantly, the possibility of elevated serum digoxin concentrations should be considered. Clinical monitoring, and possibly serum digoxin levels, during treatment with azithromycin and after its discontinuation are necessary.</p><p><strong>Zidovudine:&nbsp;</strong>Single 1000 mg doses and multiple 1200 mg or 600 mg doses of azithromycin had little effect on the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of azithromycin increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.</p><p>Azithromycin does not interact significantly with the hepatic cytochrome P450 system. It is not believed to undergo the pharmacokinetic drug interactions as seen with erythromycin and other macrolides. Hepatic cytochrome P450 induction or inactivation via cytochrome-metabolite complex does not occur with azithromycin.</p><p><strong>Ergot derivatives:</strong>&nbsp;Due to the theoretical possibility of ergotism, the concurrent use of azithromycin with ergot derivatives is not recommended (see section 4.4).</p><p>Pharmacokinetic studies have been conducted between azithromycin and the following drugs known to undergo significant cytochrome P450 mediated metabolism.</p><p><strong>Atorvastatin:</strong>&nbsp;Co-administration of atorvastatin (10 mg daily) and azithromycin (500 mg daily) did not alter the plasma concentrations of atorvastatin (based on a HMG CoA-reductase inhibition assay).</p><p><strong>Carbamazepine</strong>: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant azithromycin.</p><p><strong>Cimetidine</strong>: In a pharmacokinetic study investigating the effects of a single dose of cimetidine, given 2 hours before azithromycin, on the pharmacokinetics of azithromycin, no alteration of azithromycin pharmacokinetics was seen.</p><p><strong>Coumarin-type oral anticoagulants:</strong>&nbsp;In a pharmacokinetic interaction study, azithromycin did not alter the anticoagulant effect of a single dose of 15 mg warfarin administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulation subsequent to co-administration of azithromycin and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when azithromycin is used in patients receiving coumarin-type oral anticoagulants.</p><p><strong>Ciclosporin:&nbsp;</strong>In a pharmacokinetic study with healthy volunteers who were administered a 500 mg/day oral dose of azithromycin for 3 days and were then administered a single 10 mg/kg oral dose of ciclosporin, the resulting ciclosporin C<sub>max&nbsp;</sub>and AUC<sub>0-5&nbsp;</sub>were found to be significantly elevated (by 24% and 21% respectively), however no significant changes were seen in AUC<sub>0-&infin;</sub>. Consequently, caution should be exercised before considering concurrent administration of these drugs. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</p><p><strong>Efavirenz:</strong>&nbsp;Co-administration of a single dose of 600 mg azithromycin and 400 mg efavirenz daily for 7 days did not result in any clinically significant pharmacokinetic interactions.</p><p><strong>Fluconazole:</strong>&nbsp;Co-administration of a single dose of 1200 mg azithromycin did not alter the pharmacokinetics of a single dose of 800 mg fluconazole. Total exposure and half-life of azithromycin were unchanged by the co-administration of fluconazole, however, a clinically insignificant decrease in C<sub>max</sub>&nbsp;(18%) of azithromycin was observed.</p><p><strong>Indinavir:</strong>&nbsp;Co-administration of a single dose of 1200 mg azithromycin had no statistically significant effect on the pharmacokinetics of indinavir administered as 800 mg three times daily for 5 days.</p><p><strong>Methylprednisolone:&nbsp;</strong>In a pharmacokinetic interaction study in healthy volunteers, azithromycin had no significant effect on the pharmacokinetics of methylprednisolone.</p><p><strong>Midazolam</strong><em>:&nbsp;</em>In healthy volunteers, co-administration of 500mg/day azithromycin for 3 days did not cause clinically significant changes in the pharmacokinetics and pharmacodynamics of a single dose of 15mg midazolam.</p><p><strong>Nelfinavir:&nbsp;</strong>Co-administration of azithromycin (1200 mg) and nelfinavir at steady state (750 mg three times daily) resulted in increased azithromycin concentrations. No clinically significant adverse effects were observed and no dose adjustment was required.</p><p><strong>Rifabutin:&nbsp;</strong>Co-administration of azithromycin and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of azithromycin and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with azithromycin has not been established (see section 4.8.).</p><p><strong>Sildenafil:</strong>&nbsp;In normal healthy male volunteers, there was no evidence of an effect of azithromycin (500 mg daily for 3 days) on the AUC and C<sub>max</sub>, of sildenafil or its major circulating metabolite.</p><p><strong>Terfenadine:&nbsp;</strong>Pharmacokinetic studies have reported no evidence of an interaction between azithromycin and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however there was no specific evidence that such an interaction had occurred.</p><p><strong>Theophylline:&nbsp;</strong>There is no evidence of a clinically significant pharmacokinetic interaction when azithromycin and theophylline are co-administered to healthy volunteers.</p><p><strong>Triazolam</strong><em>:&nbsp;</em>In 14 healthy volunteers, co-administration of 500mg azithromycin on Day 1 and 250 mg on Day 2 with 0.125 mg triazolam on Day 2 had no significant effect on any of the pharmacokinetic variables for triazolam compared to triazolam and placebo.</p><p><strong>Trimethoprim/sulfamethoxazole:</strong>&nbsp;Co-administration of trimethoprim/sulfamethoxazole DS (160 mg/800 mg) for 7 days with 1200mg azithromycin on Day 7 had no significant effect on peak concentrations, total exposure or urinary excretion of either trimethoprim or sulfamethoxazole. Azithromycin serum concentrations were similar to those seen in other studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>Animal reproduction studies have been performed at doses up to moderately maternally toxic dose concentrations. In these studies, no evidence of harm to the foetus due to azithromycin was found. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, azithromycin should be used during pregnancy only if clearly needed.</p><p><u>Breast-feeding</u></p><p>There are no data on secretion in breast milk. As many drugs are excreted in human milk, azithromycin should not be used in the treatment of a lactating woman unless the physician feels that the potential benefits justify the potential risks to the infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence to suggest that Azimac may have an effect on a patient&#39;s ability to drive or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Azimac is well tolerated with a low incidence of side effects.</p><p>The section below lists the adverse reactions identified through clinical trial experience and postmarketing surveillance by system organ class and frequency. Adverse reactions identified from post-marketing experience are included in italics. The frequency grouping is defined using the following convention: Very common (&ge;1/10); Common (&ge; 1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge; 1/10,000 to &lt;1/1,000); Very Rare (&lt; 1/10,000); and Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p><strong>Adverse reactions possibly or probably related to azithromycin based on clinical trial experience and post-marketing surveillance:</strong></p><p><strong>Infections and Infestations</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Candidiasis, oral candidiasis, vaginal infection</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Pseudomembranous colitis&nbsp;</em>(see section 4.4)</p><p><strong>Blood and Lymphatic System Disorders</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge; 1/1,000 to &lt; 1/100)</em></p><p>Leukopenia, neutropenia</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Thrombocytopenia, haemolytic anaemia</em></p><p><strong>Immune System Disorders</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Angioedema, hypersensitivity</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Anaphylactic reaction</em>&nbsp;(see section 4.4)</p><p><strong>Metabolism and Nutrition Disorders</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Anorexia</p><p><strong>Psychiatric Disorders</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Nervousness</p><p><strong><em>Rare&nbsp;</em></strong><em>(&gt; 1/10000, &lt; 1/1000)</em></p><p>Agitation</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Aggression, anxiety</em></p><p><strong>Nervous System Disorders</strong></p><p><strong><em>Common&nbsp;</em></strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Dizziness, headache, paraesthesia, dysgeusia</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Hypoaesethesia, somnolence, insomnia</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Syncope, convulsion, psychomotor hyperactivity, anosmia, ageusia, parosmia, Myasthenia gravis (see section 4.4).</em></p><p><strong>Eye Disorders</strong></p><p><strong><em>Common&nbsp;</em></strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Visual impairment</p><p><strong>Ear and Labyrinth Disorders</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Deafness</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Hearing impaired, tinnitus</p><p><strong><em>Rare</em></strong><strong>&nbsp;</strong><em>(&gt; 1/10000, &lt; 1/1000)</em></p><p>Vertigo</p><p><strong>Cardiac Disorders</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&ge;1/1,000 to &lt;1/100)</em></p><p>Palpitations</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Torsades de pointes</em>&nbsp;(see section 4.4),&nbsp;<em>arrhythmia</em>&nbsp;(see section 4.4) including&nbsp;<em>ventricular tachycardia</em></p><p><strong>Vascular Disorders</strong></p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Hypotension</em></p><p><strong>Gastrointestinal Disorders</strong></p><p><strong><em>Very common</em></strong><strong>&nbsp;</strong><em>(&ge;1/10)</em></p><p>Diarrhoea, abdominal pain, nausea, flatulence</p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Vomiting, dyspepsia</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&gt; 1/1000, &lt; 1/100)</em></p><p>Gastritis, constipation</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Pancreatitis, tongue discolouration</em></p><p><strong>Hepatobiliary Disorders</strong></p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&gt; 1/1000, &lt; 1/100)</em></p><p>Hepatitis</p><p><strong><em>Rare</em></strong><strong>&nbsp;</strong><em>(&gt; 1/10000, &lt; 1/1000)</em></p><p>Hepatic function abnormal</p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Hepatic failure</em>&nbsp;(see section 4.4), which has rarely resulted in death,&nbsp;<em>hepatitis fulminant, hepatic necrosis, jaundice cholestatic</em></p><p><strong>Skin and Subcutaneous Tissue Disorders</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Pruritus and rash</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&gt; 1/1000, &lt; 1/100)</em></p><p>SJS, photosensitivity reaction, urticarial</p><p><strong><em>Rare</em></strong><strong>&nbsp;</strong><em>(&ge;1/10,000 to &lt;1/1,000)</em></p><p>Acute Generalized Exanthematous Pustulosis (AGEP)*<sup>&sect;</sup></p><p>Drug reaction with eosinophilia and systemic symptoms (DRESS)*<sup>&sect;</sup></p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p>TEN<em>, erythema multiforme</em></p><p><strong>Musculoskeletal, Connective Tissue Disorders</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Arthralgia</p><p><strong>Renal and Urinary Disorders</strong></p><p><strong><em>Not known</em></strong><strong>&nbsp;</strong><em>(cannot be estimated from available data)</em></p><p><em>Renal failure acute, nephritis interstitial</em></p><p><strong>General disorders and Administration Site Conditions</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Fatigue</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&gt; 1/1000, &lt; 1/100)</em></p><p>Chest pain, oedema, malaise, asthenia</p><p><strong>Investigations</strong></p><p><strong><em>Common</em></strong><strong>&nbsp;</strong><em>(&gt; 1/100, &lt; 1/10)</em></p><p>Lymphocyte count decreased, eosinophil count increased, blood bicarbonate decreased</p><p><strong><em>Uncommon</em></strong><strong>&nbsp;</strong><em>(&gt; 1/1000, &lt; 1/100)</em></p><p>Aspartate aminotransferase increased, alanine aminotransferase increased, blood bilirubin increased, blood urea increased, blood creatinine increased, blood potassium abnormal</p><p><strong><em>Not known&nbsp;</em></strong><em>(cannot be estimated from available data)</em></p><p><em>Electrocardiogram QT prolonged</em>&nbsp;(see section 4.4)</p><p>*ADR identified post-marketing</p><p><sup>&sect;</sup>ADR frequency represented by the estimated upper limit of the 95% confidence interval calculated using the &ldquo;Rule of 3&rdquo;.</p><p><strong><u>&nbsp;</u></strong></p><p><strong><u>Reporting of suspected adverse reactions</u></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance and Drug Safety Center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340</p><p>o Toll-free: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse events experienced in higher than recommended doses were similar to those seen at normal doses. The typical symptoms of an overdose with macrolide antibiotics include reversible loss of hearing, severe nausea, vomiting and diarrhoea. In the event of overdose, the administration of medicinal charcoal and general symptomatic treatment and supportive measures are indicated as required.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><em>General properties</em></strong></p><p>Pharmacotherapeutic group: Antibacterials for systemic use. ATC code: J01FA10</p><p><u>Mode of action:</u></p><p>Azimac is a macrolide antibiotic belonging to the azalide group. The molecule is constructed by adding a nitrogen atom to the lactone ring of erythromycin A. The chemical name of azithromycin is 9-deoxy-9a-aza-9a-methyl-9a-homoerythromycin A. The molecular weight is 749.0. The mechanism of action of azithromycin is based upon the suppression of bacterial protein synthesis by means of binding to the ribosomal 50S sub-unit and inhibition of peptide translocation.</p><p><u>Mechanism of resistance:</u></p><p>Resistance to azithromycin may be inherent or acquired. There are three main mechanisms of resistance in bacteria: target site alteration, alteration in antibiotic transport and modification of the antibiotic.</p><p>Azithromycin demonstrates cross resistance with erythromycin resistant gram positive isolates. A decrease in macrolide susceptibility over time has been noted particularly in&nbsp;<em>Streptococcus pneumoniae</em>&nbsp;and&nbsp;<em>Staphylococcus aureus</em>. Similarly, decreased susceptibility has been observed among&nbsp;<em>Streptococcus viridans</em>&nbsp;and&nbsp;<em>Streptococcus agalactiae</em>&nbsp;(Group B) streptococcus against other macrolides and lincosamides.</p><p><strong><em>Breakpoints</em></strong></p><p>Azithromycin susceptibility breakpoints for typical bacterial pathogens, as published by EUCAST are:</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2"><p><strong>Organism</strong></p></td><td colspan="2"><p><strong>MIC breakpoints (mg/L)</strong></p></td></tr><tr><td><p><strong>Susceptible (S&le;)</strong></p></td><td><p><strong>Resistant (R&gt;)</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus</em>&nbsp;spp.</p></td><td><p>1</p></td><td><p>2</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus</em>&nbsp;groups A, B, C and G</p></td><td><p>0.25</p></td><td><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p></td><td><p>0.25</p></td><td><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p></td><td><p>0.12</p></td><td><p>4</p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td><td><p>0.25</p></td><td><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td><td><p>0.25</p></td><td><p>0.5</p></td></tr></tbody></table><p><strong><em>Susceptibility</em></strong></p><p>The prevalence of acquired resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>Table: Antibacterial spectrum of Azithromycin</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Commonly susceptible species</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Staphylococcus aureus</em></p><p>Methycillin-susceptible</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p><p>Penicillin-susceptible</p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pyogenes&nbsp;</em><strong>(Group A)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-negative microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Haemophilus influenzae</em></p><p><em>Haemophilus parainfluenzae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Legionella pneumophila</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Moraxella catarrhalis</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Neisseria gonorrhoeae</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Pasteurella multocida</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Clostridium perfringens</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Fusobacterium spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Prevotella spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><em>Porphyromonas spp.</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Other microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Chlamydia trachomatis</em></p></td></tr><tr><td style="vertical-align:top"><p><strong>Species for which acquired resistance may be a problem</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Streptococcus pneumoniae</em></p><p>Penicillin-intermediate</p><p>Penicillin-resistant</p></td></tr><tr><td style="vertical-align:top"><p><strong>Inherently resistant organisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Aerobic Gram-positive microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Enterococcus faecalis</em></p></td></tr><tr><td style="vertical-align:top"><p>Staphylococci&nbsp;<strong>MRSA, MRSE</strong>*</p></td></tr><tr><td style="vertical-align:top"><p><strong>Anaerobic microorganisms</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bacteroides fragilis group</p></td></tr></tbody></table><p>* Methycillin-resistant staphylococci have a very high prevalence of acquired resistance to macrolides and have been placed here because they are rarely susceptible to azithromycin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Bioavailability after oral administration is approximately 37%. Peak plasma concentrations are attained 2 to 3 hours after taking the medicinal product.</p><p><u>Distribution</u></p><p>Orally administered azithromycin is widely distributed throughout the body. In pharmacokinetic studies it has been demonstrated that the concentrations of azithromycin measured in tissues are noticeably higher (as much as 50 times) than those measured in plasma, which indicates that the agent strongly binds to tissues.</p><p>Binding to serum proteins varies according to plasma concentration and ranges from 12% at 0.5 microgram/ml up to 52% at 0.05 microgram azithromycin/ml serum. The mean volume of distribution at steady state (VVss) has been calculated to be 31.1 l/kg.</p><p><u>Elimination</u></p><p>The terminal plasma elimination half-life closely reflects the elimination half-life from tissues of 2-4 days.</p><p>Approximately 12% of an intravenously administered dose of azithromycin is excreted unchanged in urine within the following three days. Particularly high concentrations of unchanged azithromycin have been found in human bile. Also in bile, ten metabolites were detected, which were formed through N- and O- demethylation, hydroxylation of desosamine and aglycone rings and cleavage of cladinose conjugate. Comparison of the results of liquid chromatography and microbiological analyses has shown that the metabolites of azithromycin are not microbiologically active.</p><p>In animal tests, high concentrations of azithromycin have been found in phagocytes. It has also been established that during active phagocytosis higher concentrations of azithromycin are released from inactive phagocytes. In animal models this results in high concentrations of azithromycin being delivered to the site of infection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Phospholipidosis (intracellular phospholipid accumulation) has been observed in several tissues (e.g. eye, dorsal root ganglia, liver, gallbladder, kidney, spleen, and/or pancreas) of mice, rats, and dogs given multiple doses of azithromycin. Phospholipidosis has been observed to a similar extent in the tissues of neonatal rats and dogs. The effect has been shown to be reversible after cessation of azithromycin treatment. The significance of the finding for animals and humans is unknown.</p><p><u>Carcinogenic potential:</u></p><p>Long-term studies in animals have not been performed to evaluate carcinogenic potential as the drug is indicated for short-term treatment only and there were no signs indicative of carcinogenic activity.</p><p><u>Mutagenic potential:</u></p><p>There was no evidence of a potential for genetic and chromosome mutations in in-vivo and in-vitro test models.</p><p><u>Reproductive toxicity:</u></p><p>In animal studies for embryotoxic effects of the substance, no teratogenic effect was observed in mice and rats. In rats, azithromycin doses of 100 and 200 mg/kg bodyweight/day led to mild retardation of foetal ossification and in maternal weight gain. In peri- and postnatal studies in rats, mild retardation following treatment with 50 mg/kg/day azithromycin and above was observed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Tablet core</u></strong></p><p>Calcium hydrogen phosphate</p><p>croscarmellose sodium</p><p>Maize starch</p><p>Povidone K-90</p><p>Sodium Lauryl Sulfate</p><p>Magnesium Stearate</p><p>Colloidal anhydrous silica ,</p><p>&nbsp;</p><p><strong><u>Coating</u></strong></p><p>Opadry I YS-IR -7003</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.</p><p>Do not refrigerate.</p><p>Store in the original pack to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>AZIMAC 250 mg: Opaque PVC-PVDC film / Aluminium foil blister pack of 6 tablets.</p><p>AZIMAC 500 mg: Opaque PVC-PVDC film / Aluminium foil blister pack of 3 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4/2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>